O’Neill AF, Meyers RL, Katzenstein HM, Geller JI, Tiao GM, López-Terrada D, Malogolowkin M. Children’s Oncology Group’s 2023 blueprint for research: Liver tumors. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30576. doi: 10.1002/pbc.30576. Epub 2023 Jul 26. PubMed PMID: 37495540; PubMed Central PMCID: PMC10529117.
Study ID Citation
Abstract
Liver tumors account for approximately 1–2% of all pediatric malignancies with the two most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Previous Children’s Oncology Group studies have meaningfully contributed to the current understanding of disease pathophysiology and treatment, laying groundwork for the ongoing prospective international study of both HB and HCC. Future work is focused on elucidating the biologic underpinnings of disease to support an evolution in risk categorization, advancements in the multi-dimensional care required to treat these patients, and the discovery of novel therapies.